The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity.
Open accessAbstract
N-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) produces neuropathological and clinical abnormalities in humans, monkeys, and mice that closely resemble idiopathic parkinsonism. N-Methyl-4-phenylpyridine (MPP+), a metabolite of MPTP formed by monoamine oxidase B, is accumulated into striatal and cerebral cortical synaptosomes by the dopamine and norepinephrine uptake systems, respectively, whereas MPTP itself is not accumulated. The potencies of drugs in inhibiting [3H]MPP+ or [3H]dopamine uptake into striatal synaptosomes are very similar, as are potencies in inhibiting [3H]MPP+ or [3H]norepinephrine uptake into cortical synaptosomes. The Km values for [3H]MPP+ uptake are 170 and 65 nM and the Vmax values are 2 and 0.1 nmol/g of tissue per min in rat striatum and cortex, respectively, similar to values for [3H]dopamine uptake, Autoradiography of accumulated [3H]MPP+ in slices of rat brain shows high densities in the caudate-putamen and nucleus accumbens. Furthermore, blockade of dopamine uptake by mazindol prevents MPTP-induced damage to nigrostriatal dopamine neurons, indicating that MPP+ concentration into dopamine neurons explains their selective destruction by MPTP.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PROTEIN MEASUREMENT WITH THE FOLIN PHENOL REAGENT
Lowry, O., Rosebrough, N., Farr, A. L., & Randall, R. (1951) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)52451-6 · Cited by 317,331
Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis
Langston, J. W., Ballard, P., Tetrud, J. W., & Irwin, I. (1983) · Science · doi:10.1126/science.6823561 · Cited by 4,914
Frequency Dependence of Signal Power and Spatial Reach of the Local Field Potential
Leski, S., Lindén, H., Tetzlaff, T., Pettersen, K. H., & Einevoll, G. T. (2013) · PubMed · doi:10.18154/rwth-conv-084442 · Cited by 3,639
Burns, R. S., Chiueh, C. C., Markey, S. P., Ebert, M. H., Jacobowitz, D. M., & Kopin, I. J. (1983) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.80.14.4546 · Cited by 2,149
Chronic parkinsonism secondary to intravenous injection of meperidine analogues
Davis, G. C., Williams, A. C., Markey, S. P., Ebert, M. H., Caine, E. D., Reichert, C. M., & Kopin, I. J. (1979) · Psychiatry Research · doi:10.1016/0165-1781(79)90006-4 · Cited by 1,376
Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase
Chiba, K., Trevor, A., & Castagnoli, N. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(84)91293-2 · Cited by 1,097
Heikkila, R. E., Manzino, L., Cabbat, F. S., & Duvoisin, R. C. (1984) · Nature · doi:10.1038/311467a0 · Cited by 1,010
Dopaminergic Neurotoxicity of 1-Methyl-4-Phenyl-1,2,5,6-Tetrahydropyridine in Mice
Heikkila, R. E., Hess, A., & Duvoisin, R. C. (1984) · Science · doi:10.1126/science.6610213 · Cited by 1,009
William Langston, J., Forno, L. S., Rebert, C. S., & Irwin, I. (1984) · Brain Research · doi:10.1016/0006-8993(84)90777-7 · Cited by 922
A practical computer-based approach to the analysis of radioligand binding experiments
McPherson, G. A. (1983) · Computer Programs in Biomedicine · doi:10.1016/0010-468x(83)90031-4 · Cited by 829
Cited by
Dauer, W., & Przedborski, S. (2003) · Neuron · doi:10.1016/s0896-6273(03)00568-3 · Cited by 5,469
The Roles of PINK1, Parkin, and Mitochondrial Fidelity in Parkinson’s Disease
Pickrell, A. M., & Youle, R. J. (2015) · Neuron · doi:10.1016/j.neuron.2014.12.007 · Cited by 2,310
“The autophagosome is then delivered to the lysosome for degradation. a mitochondrial respiratory chain component of the oxidative phosphorylation (OXPHOS) machinery (Javitch et al., 1985; Nicklas et al., 1985; Ramsay and Singer, 1986).”
BackgroundMitochondrial Complex I Deficiency in Parkinson's Disease
Schapira, A. H. V., Cooper, J. M., Dexter, D., Clark, J. B., Jenner, P., & Marsden, C. D. (1990) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1990.tb02325.x · Cited by 2,283
MITOCHONDRIAL COMPLEX I DEFICIENCY IN PARKINSON'S DISEASE
Schapira, A. H. V., Cooper, J. M., Dexter, D., Jenner, P., Clark, J. B., & Marsden, C. D. (1989) · The Lancet · doi:10.1016/s0140-6736(89)92366-0 · Cited by 1,756
Alpha-synuclein and neurodegenerative diseases
Goedert, M. (2001) · Nature Reviews Neuroscience · doi:10.1038/35081564 · Cited by 1,408
Protocol for the MPTP mouse model of Parkinson's disease
Jackson-Lewis, V., & Przedborski, S. (2007) · Nature Protocols · doi:10.1038/nprot.2006.342 · Cited by 1,111
Expression cloning of a cocaine-and antidepressant-sensitive human noradrenaline transporter
Pacholczyk, T., Blakely, R. D., & Amara, S. G. (1991) · Nature · doi:10.1038/350350a0 · Cited by 933
Bendor, J. T., Logan, T. P., & Edwards, R. H. (2013) · Neuron · doi:10.1016/j.neuron.2013.09.004 · Cited by 825
Pisoschi, A. M., Pop, A., Iordache, F., Stanca, L., Predoi, G., & Serban, A. I. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112891 · Cited by 816
Classic toxin-induced animal models of Parkinson?s disease: 6-OHDA and MPTP
Schober, A. (2004) · Cell and Tissue Research · doi:10.1007/s00441-004-0938-y · Cited by 803
Duty, S., & Jenner, P. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01426.x · Cited by 753
Mitochondrial dysfunction in Parkinson's disease
Winklhofer, K. F., & Haass, C. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.08.013 · Cited by 688
Schapira, A. H. V., Mann, V. M., Cooper, J. M., Dexter, D., Daniel, S. E., Jenner, P., Clark, J. B., & Marsden, C. D. (1990) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1990.tb05809.x · Cited by 673
Przedborski, S., Jackson-Lewis, V, Yokoyama, R., Shibata, T., Dawson, V. L., & Dawson, T. M. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.10.4565 · Cited by 624
Jackson-Lewis, V., Jakowec, M., Burke, R. E., & Przedborski, S. (1995) · Neurodegeneration · doi:10.1016/1055-8330(95)90015-2 · Cited by 609
A cDNA that suppresses MPP+ toxicity encodes a vesicular amine transporter
Liu, Y. (1992) · Cell · doi:10.1016/0092-8674(92)90425-c · Cited by 594
Animal models of Parkinson's disease
Betarbet, R., Sherer, T. B., & Greenamyre, J. T. (2002) · BioEssays · doi:10.1002/bies.10067 · Cited by 592
Li, Y., Perry, T., Kindy, M. S., Harvey, B. K., Tweedie, D., Holloway, H. W., Powers, K., Shen, H., Egan, J. M., Sambamurti, K., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806720106 · Cited by 589
“Administration of MPTP in mice induces a consistent dopaminergic cell loss that parallels many aspects of PD (16,20).”
BackgroundAdvances in Our Understanding of the Mechanisms of the Neurotoxicity of MPTP and Related Compounds
Tipton, K. F., & Singer, T. P. (1993) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1993.tb13610.x · Cited by 539
Fornai, F., Schlüter, O. M., Lenzi, P., Gesi, M., Ruffoli, R., Ferrucci, M., Lazzeri, G., Busceti, C. L., Pontarelli, F., Battaglia, G., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409713102 · Cited by 526
Przedborski, S., Jackson‐Lewis, V., Naini, A. B., Jakowec, M., Petzinger, G., Miller, R., & Akram, M. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00183.x · Cited by 507
Neurotoxin-based models of Parkinson's disease
Bové, J., & Perier, C. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2011.10.057 · Cited by 506
Classic and New Animal Models of Parkinson's Disease
Blesa, J., Phani, S., Jackson-Lewis, V., & Przedborski, S. (2012) · Journal of Biomedicine and Biotechnology · doi:10.1155/2012/845618 · Cited by 505
Distinct Monoamine Oxidase A and B Populations in Primate Brain
Westlund, K. N., Denney, R. M., Kochersperger, L. M., Rose, R. M., & Abell, C. W. (1985) · Science · doi:10.1126/science.3875898 · Cited by 504
Invited Review Free radicals and the pathobiology of brain dopamine systems
Cadet, J. L., & Brannock, C. (1998) · Neurochemistry International · doi:10.1016/s0197-0186(97)00031-4 · Cited by 499
Oxidative stress and cellular pathologies in Parkinson’s disease
Puspita, L., Chung, S. Y., & Shim, J.-W. (2017) · Molecular Brain · doi:10.1186/s13041-017-0340-9 · Cited by 483
Oxidative stress: Free radical production in neural degeneration
Götz, M. E., Künig, G., Riederer, P., & Youdim, M. B. H. (1994) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(94)90055-8 · Cited by 482
Nirenberg, M., Vaughan, R., Uhl, G., Kuhar, M., & Pickel, V. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-02-00436.1996 · Cited by 480
Erickson, J. D., Schafer, M. K., Bonner, T. I., Eiden, L. E., & Weihe, E. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.10.5166 · Cited by 479
Giros, B., el Mestikawy, S., Godinot, N., Zheng, K., Han, H., Yang-Feng, T., & Caron, M. G. (1992) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)08925-4 · Cited by 477
Spina, M. B., Squinto, S. P., Miller, J., Lindsay, R. M., & Hyman, C. (1992) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1992.tb08880.x · Cited by 460
The Role of Environmental Exposures in Neurodegeneration and Neurodegenerative Diseases
Cannon, J. R., & Greenamyre, J. T. (2011) · Toxicological Sciences · doi:10.1093/toxsci/kfr239 · Cited by 459
Przedborski, S., Kostic, V, Jackson-Lewis, V, Naini, A., Simonetti, S., Fahn, S., Carlson, E., Epstein, C., & Cadet, J. (1992) · The Journal of Neuroscience · doi:10.1523/jneurosci.12-05-01658.1992 · Cited by 456
LEE, F. J. S., LIU, F., PRISTUPA, Z. B., & NIZNIK, H. B. (2001) · The FASEB Journal · doi:10.1096/fj.00-0334com · Cited by 455
Recent Advances in the Genetics of Parkinson's Disease
Martin, I., Dawson, V. L., & Dawson, T. M. (2011) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-082410-101440 · Cited by 437
D-β-Hydroxybutyrate rescues mitochondrial respiration and mitigates features of Parkinson disease
Tieu, K., Perier, C., Caspersen, C., Teismann, P., Wu, D.-C., Yan, S.-D., Naini, A., Vila, M., Jackson-Lewis, V., Ramasamy, R., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200318797 · Cited by 497
Neurotoxin-induced degeneration of dopamine neurons in Caenorhabditis elegans
Nass, R., Hall, D. H., Miller, D. M., & Blakely, R. D. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.042497999 · Cited by 417
Ramsay, R. R., & Singer, T. P. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)57434-8 · Cited by 412
Oxidative Stress and Genetics in the Pathogenesis of Parkinson's Disease
Zhang, Y., Dawson, V. L., & Dawson, T. M. (2000) · Neurobiology of Disease · doi:10.1006/nbdi.2000.0319 · Cited by 407
Tillerson, J. L., Caudle, W. M., Reverón, M. E., & Miller, G. W. (2003) · Neuroscience · doi:10.1016/s0306-4522(03)00096-4 · Cited by 399
Mandir, A. S., Przedborski, S., Jackson-Lewis, V., Wang, Z.-Q., Simbulan-Rosenthal, C. M., Smulson, M. E., Hoffman, B. E., Guastella, D. B., Dawson, V. L., & Dawson, T. M. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.10.5774 · Cited by 382
Monzio Compagnoni, G., Di Fonzo, A., Corti, S., Comi, G. P., Bresolin, N., & Masliah, E. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-01926-1 · Cited by 378
Dopamine transporters and neuronal injury
Miller, G. W., Gainetdinov, R. R., Levey, A. I., & Caron, M. G. (1999) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(99)01379-6 · Cited by 371
Monte, D. A. D. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00501-5 · Cited by 361
Westlund, K. N., Denney, R. M., Rose, R. M., & Abell, C. W. (1988) · Neuroscience · doi:10.1016/0306-4522(88)90250-3 · Cited by 354
Platelet mitochondria function in Parkinson's disease
Krige, D., Carroll, M. T., Cooper, J. M., Marsden, C. D., Schapira, A. H. V., & (The Royal Kings Queens Parkinson Disease Research Group) (1992) · Annals of Neurology · doi:10.1002/ana.410320612 · Cited by 352
Oxidative stress and antioxidant therapy in Parkinson's disease
Ebadi, M., Srinivasan, S. K., & Baxi, M. D. (1996) · Progress in Neurobiology · doi:10.1016/0301-0082(95)00029-1 · Cited by 336
Damage to dopaminergic neurons by oxidative stress in Parkinson's disease (Review)
Guo, J., Zhao, X., Li, Y., Li, G., & Liu, X. (2018) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2018.3406 · Cited by 335
Differential expression of two vesicular monoamine transporters
Peter, D., Liu, Y., Sternini, C., de Giorgio, R., Brecha, N., & Edwards, R. (1995) · The Journal of Neuroscience · doi:10.1523/jneurosci.15-09-06179.1995 · Cited by 333
Chronic systemic complex I inhibition induces a hypokinetic multisystem degeneration in rats
Höglinger, G. U., Féger, J., Prigent, A., Michel, P. P., Parain, K., Champy, P., Ruberg, M., Oertel, W. H., & Hirsch, E. C. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01533.x · Cited by 331
Glutamate and Parkinson’s disease
Blandini, F., Porter, R. H. P., & Greenamyre, J. T. (1996) · Molecular Neurobiology · doi:10.1007/bf02740748 · Cited by 323
Drechsel, D. A., & Patel, M. (2008) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2008.02.008 · Cited by 314
MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease
Gerlach, M., Riederer, P., Przuntek, H., & Youdim, M. B. H. (1991) · European Journal of Pharmacology: Molecular Pharmacology · doi:10.1016/0922-4106(91)90073-q · Cited by 307
The Parkinsonism-inducing Drug 1-Methyl-4-phenylpyridinium Triggers Intracellular Dopamine Oxidation
Lotharius, J., & O'Malley, K. L. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m005385200 · Cited by 306
Cassarino, D. S., Parks, J. K., Parker, W. D., & Bennett, J. P. (1999) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(98)00083-0 · Cited by 304
Heikkila, R. E., Nicklas, W. J., Vyas, I., & Duvoisin, R. C. (1985) · Neuroscience Letters · doi:10.1016/0304-3940(85)90580-4 · Cited by 300
Testa, C. M., Sherer, T. B., & Greenamyre, J. T. (2005) · Molecular Brain Research · doi:10.1016/j.molbrainres.2004.11.007 · Cited by 299
Mitochondrial dysfunction and oxidative stress in aging and neurodegenerative disease
Albers, D. S., & Flint Beal, M. (2000) · Advances in Dementia Research · doi:10.1007/978-3-7091-6781-6_16 · Cited by 297
Selectivity of the Parkinsonian Neurotoxin MPTP: Toxic Metabolite MPP + Binds to Neuromelanin
D'Amato, R. J., Lipman, Z. P., & Snyder, S. H. (1986) · Science · doi:10.1126/science.3080808 · Cited by 296
Self-citationTHE ROLE OF VESICULAR TRANSPORT PROTEINS IN SYNAPTIC TRANSMISSION AND NEURAL DEGENERATION
Liu, Y., & Edwards, R. H. (1997) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.20.1.125 · Cited by 296
MPTP Toxicity: Implications for Research in Parkinson's Disease
Kopin, I. J., & Markey, S. P. (1988) · Annual Review of Neuroscience · doi:10.1146/annurev.ne.11.030188.000501 · Cited by 295
Neurochemical findings in the MPTP model of Parkinson's disease
Schmidt, N., & Ferger, B. (2001) · Journal of Neural Transmission · doi:10.1007/s007020100004 · Cited by 290
Parkinson's disease: A case‐control study of occupational and environmental risk factors
Hertzman, C., Wiens, M., Bowering, D., Snow, B., & Calne, D. (1990) · American Journal of Industrial Medicine · doi:10.1002/ajim.4700170307 · Cited by 290
Oxidative damage in nucleic acids and Parkinson's disease
Nakabeppu, Y., Tsuchimoto, D., Yamaguchi, H., & Sakumi, K. (2007) · Journal of Neuroscience Research · doi:10.1002/jnr.21191 · Cited by 290
MPTP as a Mitochondrial Neurotoxic Model of Parkinson's Disease
Przedborski, S., Tieu, K., Perier, C., & Vila, M. (2004) · Journal of Bioenergetics and Biomembranes · doi:10.1023/b:jobb.0000041771.66775.d5 · Cited by 287
Cell death pathways in Parkinson’s disease: proximal triggers, distal effectors, and final steps
Levy, O. A., Malagelada, C., & Greene, L. A. (2009) · Apoptosis · doi:10.1007/s10495-008-0309-3 · Cited by 287
PRZEDBORSKI, S., & VILA, M. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb07476.x · Cited by 283
Marchitti, S. A., Deitrich, R. A., & Vasiliou, V. (2007) · Pharmacological Reviews · doi:10.1124/pr.59.2.1 · Cited by 280
Giasson, B. I., Ischiropoulos, H., Lee, V. M.-Y., & Trojanowski, J. Q. (2002) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(02)00804-3 · Cited by 279
Immunohistochemical studies on complexes I, II, III, and IV of mitochondria in parkinson's disease
Hattori, N., Tanaka, M., Ozawa, T., & Mizuno, Y. (1991) · Annals of Neurology · doi:10.1002/ana.410300409 · Cited by 276
The role of Toll-like receptors and neuroinflammation in Parkinson’s disease
Heidari, A., Yazdanpanah, N., & Rezaei, N. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02496-w · Cited by 275
“Within DA neurons, MPP + affects mitochondrial function leading to oxidative stress and degeneration of DA neurons [73, 75].”
BackgroundParaquat Neurotoxicity is Distinct from that of MPTP and Rotenone
Richardson, J. R., Quan, Y., Sherer, T. B., Greenamyre, J. T., & Miller, G. W. (2005) · Toxicological Sciences · doi:10.1093/toxsci/kfi304 · Cited by 275
Crocker, S. J., Smith, P. D., Jackson-Lewis, V., Lamba, W. R., Hayley, S. P., Grimm, E., Callaghan, S. M., Slack, R. S., Melloni, E., Przedborski, S., et al. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-10-04081.2003 · Cited by 274
Oxygen Free Radicals and Brain Dysfunction
Jesberger, J. A., & Richardson, J. S. (1991) · International Journal of Neuroscience · doi:10.3109/00207459109150342 · Cited by 273
Saporito, M. S., Brown, E. M., Miller, M. S., & Carswell, S. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37972-8 · Cited by 266
Carrier-mediated processes in blood–brain barrier penetration and neural uptake of paraquat
Shimizu, K., Ohtaki, K., Matsubara, K., Aoyama, K., Uezono, T., Saito, O., Suno, M., Ogawa, K., Hayase, N., Kimura, K., et al. (2001) · Brain Research · doi:10.1016/s0006-8993(01)02577-x · Cited by 263
Inden, M., Kitamura, Y., Takeuchi, H., Yanagida, T., Takata, K., Kobayashi, Y., Taniguchi, T., Yoshimoto, K., Kaneko, M., Okuma, Y., et al. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04440.x · Cited by 260
Neurodegeneration and neuroprotection in Parkinson disease
Fahn, S., & Sulzer, D. (2004) · NeuroRX · doi:10.1602/neurorx.1.1.139 · Cited by 257
Höglinger, G. U., Carrard, G., Michel, P. P., Medja, F., Lombès, A., Ruberg, M., Friguet, B., & Hirsch, E. C. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01952.x · Cited by 253
Mitochondrial dysfunction in the limelight of Parkinson's disease pathogenesis
Banerjee, R., Starkov, A. A., Beal, M. F., & Thomas, B. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2008.11.007 · Cited by 253
Enzymatic Oxidation of Xenobiotic Chemical
Peter Guengerich, F. (1990) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409239009090607 · Cited by 253
Truban, D., Hou, X., Caulfield, T. R., Fiesel, F. C., & Springer, W. (2016) · Journal of Parkinson’s Disease · doi:10.3233/jpd-160989 · Cited by 237
Minocycline Enhances MPTP Toxicity to Dopaminergic Neurons
Yang, L., Sugama, S., Chirichigno, J. W., Gregorio, J., Lorenzl, S., Shin, D. H., Browne, S. E., Shimizu, Y., Joh, T. H., Beal, M. F., et al. (2003) · Journal of Neuroscience Research · doi:10.1002/jnr.10709 · Cited by 158
RNA oxidation in Alzheimer disease and related neurodegenerative disorders
Nunomura, A., Hofer, T., Moreira, P. I., Castellani, R. J., Smith, M. A., & Perry, G. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0508-1 · Cited by 148
Lin, C., Tai, Y., Huang, M., Tsai, Y., Hsu, H., Tzen, K., & Liou, H. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06801.x · Cited by 119
Cragg, S. J., Rice, M. E., & Greenfield, S. A. (1997) · Journal of Neurophysiology · doi:10.1152/jn.1997.77.2.863 · Cited by 118
Schildknecht, S., Pöltl, D., Nagel, D. M., Matt, F., Scholz, D., Lotharius, J., Schmieg, N., Salvo-Vargas, A., & Leist, M. (2009) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2009.07.027 · Cited by 115
Coenzyme Q10 and nicotinamide and a free radical spin trap protect against MPTP neurotoxicity
Schulz, J. B., Ross Henshaw, D., Matthews, R. T., & Flint Beal, M. (1995) · Experimental Neurology · doi:10.1016/0014-4886(95)90033-0 · Cited by 103
Rational therapeutic approaches to progressive supranuclear palsy
Stamelou, M., de Silva, R., Arias-Carrion, O., Boura, E., Hollerhage, M., Oertel, W. H., Muller, U., & Hoglinger, G. U. (2010) · Brain · doi:10.1093/brain/awq115 · Cited by 91
Machado, V., Zöller, T., Attaai, A., & Spittau, B. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17020151 · Cited by 76
“Th-ir (Tyrosine hydroxylase-immunoreactive) mDA neurons and other catecholaminergic neurons are especially sensitive to MPTP-induced degeneration due to the selective uptake of MPP+ by the dopamine transporter (DAT) and noradrenaline and serotonin transporters [20–22].”
BackgroundShang, T., Kotamraju, S., Kalivendi, S. V., Hillard, C. J., & Kalyanaraman, B. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m400101200 · Cited by 62
Acetyl-levo-carnitine protects against MPTP-induced parkinsonism in primates
Bodis-Wollner, I., Chung, E., Ghilardi, M. F., Glover, A., Onofrj, M., Pasik, P., & Samson, Y. (1991) · Journal of Neural Transmission - Parkinson's Disease and Dementia Section · doi:10.1007/bf02251137 · Cited by 51
Watanabe, H., Dijkstra, J. M., & Nagatsu, T. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25042009 · Cited by 48
Rifampicin Attenuates the MPTP-Induced Neurotoxicity in Mouse Brain
Oida, Y., Kitaichi, K., Nakayama, H., Ito, Y., Fujimoto, Y., Shimazawa, M., Nagai, H., & Hara, H. (2006) · Brain Research · doi:10.1016/j.brainres.2006.01.116 · Cited by 47
Conklin, B., Conley, B. M., Hou, Y., Chen, M., & Lee, K.-B. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114636 · Cited by 45
Langston, J. W., Forno, L. S., Tetrud, J., Reeves, A. G., Kaplan, J. A., & Karluk, D. (1999) · Annals of Neurology · doi:10.1002/1531-8249(199910)46:4 · Cited by 1
Metadata
- Authors
- Javitch, J. A., D'Amato, R. J., Strittmatter, S. M., & Snyder, S. H.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1985-04
- Volume
- 82
- Issue
- 7
- Pages
- 2173-2177
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2038557175
- Cited by
- 1,263
- References
- 30
- FWCI
- 43.81
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.